Lannett Company, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lannett Company, Inc.
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.
In a busy period for Lannett, the company has benefited from a US shortage of generic Adderall rivals as well as a “more favorable pricing environment” to enjoy better results than expected – albeit with sales still significantly down on last year.
- Generic Drugs
- Other Names / Subsidiaries
- Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals